In:
Journal of Bone and Mineral Research, Wiley, Vol. 38, No. 9 ( 2023-09), p. 1312-1321
Kurzfassung:
In a 36‐month randomized controlled trial examining the effect of high‐dose vitamin D 3 on radial and tibial total bone mineral density (TtBMD), measured by high‐resolution peripheral quantitative tomography (HR‐pQCT), participants (311 healthy males and females aged 55–70 years with dual‐energy X‐ray absorptiometry T‐scores 〉 −2.5 without vitamin D deficiency) were randomized to receive 400 IU ( N = 109), 4000 IU ( N = 100), or 10,000 IU ( N = 102) daily. Participants had HR‐pQCT radius and tibia scans and blood sampling at baseline, 6, 12, 24, and 36 months. This secondary analysis examined the effect of vitamin D dose on plasma measurements of the vitamin D metabolome by liquid chromatography–tandem mass spectrometry (LC‐MS/MS), exploring whether the observed decline in TtBMD was associated with changes in four key metabolites [25‐(OH)D 3 ; 24,25‐(OH) 2 D 3 ; 1,25‐(OH) 2 D 3 ; and 1,24,25‐(OH) 3 D 3 ]. The relationship between peak values in vitamin D metabolites and changes in TtBMD over 36 months was assessed using linear regression, controlling for sex. Increasing vitamin D dose was associated with a marked increase in 25‐(OH)D 3 , 24,25‐(OH) 2 D 3 and 1,24,25‐(OH) 3 D 3 , but no dose‐related change in plasma 1,25‐(OH) 2 D 3 was observed. There was a significant negative slope for radius TtBMD and 1,24,25‐(OH) 3 D 3 (−0.05, 95% confidence interval [CI] −0.08, −0.03, p 〈 0.001) after controlling for sex. A significant interaction between TtBMD and sex was seen for 25‐(OH)D 3 (female: −0.01, 95% CI −0.12, −0.07; male: −0.04, 95% CI −0.06, −0.01, p = 0.001) and 24,25‐(OH) 2 D 3 (female: −0.75, 95% CI −0.98, −0.52; male: −0.35, 95% CI −0.59, −0.11, p 〈 0.001). For the tibia there was a significant negative slope for 25‐(OH)D 3 (−0.03, 95% CI −0.05, −0.01, p 〈 0.001), 24,25‐(OH) 2 D 3 (−0.30, 95% CI −0.44, −0.16, p 〈 0.001), and 1,24,25‐(OH) 3 D 3 (−0.03, 95% CI −0.05, −0.01, p = 0.01) after controlling for sex. These results suggest vitamin D metabolites other than 1,25‐(OH) 2 D 3 may be responsible for the bone loss seen in the Calgary Vitamin D Study. Although plasma 1,25‐(OH) 2 D 3 did not change with vitamin D dose, it is possible rapid catabolism to 1,24,25‐(OH) 3 D 3 prevented the detection of a dose‐related rise in plasma 1,25‐(OH) 2 D 3 . © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Materialart:
Online-Ressource
ISSN:
0884-0431
,
1523-4681
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2023
ZDB Id:
2008867-X
Permalink